Cargando…
Dupilumab for Chronic Prurigo: Case Series on Effectiveness, Safety, and Quality of Life
BACKGROUND: Chronic prurigo (CPG) is a pruritic skin disease, characterized by an itch-scratch cycle and scarring. It reduces patients’ quality of life (QoL). Dupilumab is a monoclonal human IgG antibody that inhibits signaling of the interleukin 4 (IL-4) and interleukin 13 (IL-13) pathways through...
Autores principales: | Richter, Clara, Hafner, Jürg, Schuermann, Manuel, Tanadini, Matteo, Trisconi, Nisia, Schmid-Grendelmeier, Peter, Kündig, Thomas, Nägeli, Mirjam, Brüggen, Marie-Charlotte, Guillet, Carole |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
S. Karger AG
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10614240/ https://www.ncbi.nlm.nih.gov/pubmed/37369187 http://dx.doi.org/10.1159/000531708 |
Ejemplares similares
-
Dupilumab for Chronic Prurigo in Different Backgrounds: A Case Series
por: Luo, Nana, et al.
Publicado: (2022) -
Recalcitrant prurigo nodularis treated successfully with dupilumab
por: Rambhia, Pooja H., et al.
Publicado: (2019) -
Resolution of Treatment-Refractory Prurigo Nodularis With Dupilumab: A Case Series
por: Wieser, Jill K, et al.
Publicado: (2020) -
Simultaneous treatment of Samter triad and prurigo nodularis with dupilumab
por: Bloomstein, Joshua D., et al.
Publicado: (2021) -
Erfolgreiche Behandlung einer chronischen Prurigo mit Dupilumab
por: Winkler, Julia K., et al.
Publicado: (2020)